Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia

Shikha Dwivedi; Vimal Kumar Dixit; Shalu Bawa; Mirza Atif Beg; Dilip Chandra Dhasmana

doi:10.5455/njppp.2022.12.10359202126102021

2023, Vol: 13, Issue: 5

13/5Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Natl J Physiol Pharm Pharmacol. 2022; 12(5): 588-591

doi: 10.5455/njppp.2022.12.10359202126102021

Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia

Shikha Dwivedi, Vimal Kumar Dixit, Shalu Bawa, Mirza Atif Beg, Dilip Chandra Dhasmana.

Abstract
Background: Lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) is a common problem among aging men. Several classes of drugs are efficacious and safe, but the first-line treatment is with alpha-1 adrenergic blockers. They provide symptomatic relief and have to be taken for a longer duration to sustain the effect. The preferred alpha-blockers among the stockpile should be efficacious, tolerable, and also cost-effective.

Aim and Objective: This study focuses to compare the cost-effectiveness of various alpha blockers prescribed in patients with LUTS-BPH.

Materials and Methods: An observational study of 78 patients who were newly diagnosed with LUTS-BPH from April 2014 to May 2015 was conducted. Patients were followed up at 4 weeks and at 12 weeks after the drugs had been prescribed. Efficacy assessment was done on basis of change in International Prostate Symptom Score (IPSS) score over 12 weeks. Average cost-effectiveness ratio of different alpha-blockers prescribed was evaluated and compared with Mann-Whitney U test in order to find the most cost-effective alpha-blocker in the study.

Results: All patients were prescribed alpha-blockers either alone or in combination with other drugs. Tamsulosin was prescribed to n = 46, Silodosin to n = 16 and Alfuzosin to n = 16. The efficacy in terms of Mean change in IPSS after 12 weeks of study was 11.34 ± 5.23 for Tamsulosin, 11.70 ± 5.9 for Silodosin and 10.87 ± 4.77 for Alfuzosin and average cost-effectiveness ratio was 108.74, 183.07 and 127.50 for Tamsulosin, Silodosin, and Alfuzosin, respectively.

Conclusion: Tamsulosin was the most cost-effective drug among the prescribed alpha-blockers. Since all the prescribed alpha-blockers had comparable efficacy so we concluded that the most cost-effective drug should be preferred for long-duration treatment.

Key words: Alpha Blockers; Tamsulosin; Silodosin; Alfuzosin; Cost-effectiveness; Lower urinary tract symptom-Benign Prostatic Hyperplasia

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Shikha Dwivedi Articles by Vimal Kumar Dixit Articles by Shalu Bawa Articles by Mirza Atif Beg Articles by Dilip Chandra Dhasmana
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Dwivedi S, Dixit VK, Bawa S, Beg MA, Dhasmana DC. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. Natl J Physiol Pharm Pharmacol. 2022; 12(5): 588-591. doi:10.5455/njppp.2022.12.10359202126102021

Web Style

Dwivedi S, Dixit VK, Bawa S, Beg MA, Dhasmana DC. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. https://www.njppp.com/?mno=84968 [Access: May 01, 2023]. doi:10.5455/njppp.2022.12.10359202126102021

AMA (American Medical Association) Style

Dwivedi S, Dixit VK, Bawa S, Beg MA, Dhasmana DC. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. Natl J Physiol Pharm Pharmacol. 2022; 12(5): 588-591. doi:10.5455/njppp.2022.12.10359202126102021

Vancouver/ICMJE Style

Dwivedi S, Dixit VK, Bawa S, Beg MA, Dhasmana DC. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. Natl J Physiol Pharm Pharmacol. (2022), [cited May 01, 2023]; 12(5): 588-591. doi:10.5455/njppp.2022.12.10359202126102021

Harvard Style

Dwivedi, S., Dixit, . V. K., Bawa, . S., Beg, . M. A. & Dhasmana, . D. C. (2022) Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. Natl J Physiol Pharm Pharmacol, 12 (5), 588-591. doi:10.5455/njppp.2022.12.10359202126102021

Turabian Style

Dwivedi, Shikha, Vimal Kumar Dixit, Shalu Bawa, Mirza Atif Beg, and Dilip Chandra Dhasmana. 2022. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. National Journal of Physiology, Pharmacy and Pharmacology, 12 (5), 588-591. doi:10.5455/njppp.2022.12.10359202126102021

Chicago Style

Dwivedi, Shikha, Vimal Kumar Dixit, Shalu Bawa, Mirza Atif Beg, and Dilip Chandra Dhasmana. "Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 588-591. doi:10.5455/njppp.2022.12.10359202126102021

MLA (The Modern Language Association) Style

Dwivedi, Shikha, Vimal Kumar Dixit, Shalu Bawa, Mirza Atif Beg, and Dilip Chandra Dhasmana. "Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia." National Journal of Physiology, Pharmacy and Pharmacology 12.5 (2022), 588-591. Print. doi:10.5455/njppp.2022.12.10359202126102021

APA (American Psychological Association) Style

Dwivedi, S., Dixit, . V. K., Bawa, . S., Beg, . M. A. & Dhasmana, . D. C. (2022) Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. National Journal of Physiology, Pharmacy and Pharmacology, 12 (5), 588-591. doi:10.5455/njppp.2022.12.10359202126102021

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



Copyright © 2023 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology. For best results, please use Internet Explorer or Google Chrome	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272

Contact Information

How to cite this article